Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the ...

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Joe Kiani Co-Founder Masimo Corp. The latest legal battle between Irvine-based medical device maker Masimo Corp. and Apple ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Wells Fargo analyst Vik Chopra has assigned their bullish stance on MASI stock, giving a Buy rating yesterday. Vik Chopra has given his Buy ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Masimo (MASI) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.63 per share a year ago. These figures are ...

Masimo Corp. (MASI) on Tuesday reported third-quarter earnings of $9.8 million. On a per-share basis, the Irvine, California-based company said it had ...

The tech giant also allegedly attempted to hire away key employees, including Cercacor’s former chief technology officer and ...

such as Rad-97 ® and the Masimo W1 ® Medical Watch. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation ™ platform, and include Iris ® ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.